Conference Information

Welcome Message

In the wake of the successful completion of our conference in Orlando, USA. We are proudly announcing our 8th International conference on Virology, Influenza, and Infectious diseases which is to be held on the beautiful days of May 29-31, 2023 In Madrid, Spain. We are gratefully waiting for your participation at our conference and make our conference a great work as our previous event which made us proud in the world and paved many young minds with new ideas and make them more efficient in thinking.

The virology 2023 mainly focuses on and works based on the theme “Discovering and Combating the Latest Research innovations In Virology”.

The virology 2023 has many chances to meet many eminent persons and great influential speakers with great knowledge of the topic.

The two-day scientific virology 2023 covers recent scientific results that either support or contradict the efficacy of existing or projected technologies, services and uses. Unique strains, contentious but scientifically sound concepts, techniques, and visions will also be discussed in the presentations, keynote speeches, plenary talks, discussion forums, symposiums, and invited talks. These topics will help to improve healthcare and increase the efficiency with which viruses are used in research and development.

The virology 2023 main objectives are to promote the most recent advances, research, and breakthroughs, examine difficulties in fields connected to virology and bacteriology, and exchange innovations and ideas on pathology for further study and more potent therapies.

We have a panel of Eminent Organization Committee Members who can make your ideas more accurate and help you with whatever problems you are facing or have to face in the study of the topic and they will be able to guide you in a correct research pathway

The virology 2023 will cover some of the most important virology-related topics and look at the support required to guarantee that the general population receives the best care possible and can look forward to a promising future. Our conference seeks to give the ideal stage for presenting enlightening Keynote lectures, Plenary sessions, and Workshops. It also intends to build connections and foster idea exchange.

According to a recent estimate, there are 3,20,000 mammalian viruses, many of which can transmit to humans, and anyone poses a threat to a person’s life.

The virology 2023 is to be held with a group of like-minded individuals, we hope to highlight recent developments in virology and infectious diseases.

As the COVID-19 outbreak enters its third year, the essential importance of virology to all sectors of human endeavor is clear than ever. The pandemic highlights both the detrimental consequences that viruses can have on human health and activities as well as how swiftly advancements in research can mitigate the worst effects. While everyone has had the COVID-19 pandemic on their minds, we shouldn't ignore the significance of other viral diseases or the utility of viruses or viral components that can be employed to fulfill beneficial and vital roles. Additionally, we shouldn't downplay the role that viral systems play in studies in a variety of biomedical fields, such as molecular and cell biology, chemical biology, immunology, evolutionary biology, and structural biology.

All attendees will have the chance to debate research concepts with experts, keynote speakers, delegates, guests, writers, academics, CEOs, scientists, and illustrious physicians, as well as to take part in a range of conversations that will help define future health policy and appropriate patient care throughout the world.

We are confident that our conference will be a great platform to enlighten your knowledge and you are welcome to experience the great days in Madrid.

Regards

Jordan Diaz

Program Manager | Virology 2023

About Conference

The 8th International Conference on Virology, Influenza, and Infectious Diseases welcome’s pathologists, R&D companies, Ph.D. scholars, physicians, healthcare companies, medical equipment companies laboratory medicine societies, advertising companies, surgeons, researchers, scientists, business delegates, Laboratory Medicine institutions, companies and clinics, Medical Colleges, Faculties, Associations, Diagnostics centers, Pharmaceutical Industries, Product development and marketing professionals, Healthcare Industries, Medical devices manufacturing companies. The focus of the conference is to address the “Novel strategies for surveillance against emerging Viral diseases.”

Delegates from colleges and institutions will get a great chance to network with top surgeons, lab experts, academic pathologists, researchers, and businesses at Virology 2023. Bringing together well-known speakers and connecting scientists and researchers from all over the world is our aim. We offer a space for the exchange of ideas on the majority of virology disorders, as well as the capacity for researchers to think creatively across several dimensions. It's excellent research gathering for highly viral diseases that are now prevalent.

Meeting scientists, authorities, and CROs from all over the world at the 8th International Conference on Virology, Influenza, and Infectious Diseases 2023 is a great way to expand your network. Attending Virology 2023 is a crucial way to take advantage of the chance to advance your research interests. We are looking forward to your suggestions and an unrelenting dedication to making the Virology 2023 grant a success.

Why should you Attend:

With Virology 2023, You will be able to gain a strategic advantage and be the first to present your knowledge, innovations, and brand. Reach your targeted audience and encourage individuals to discover further about your services, and products, meet with experts, Study in a New Setting, New Techniques & Tips, Certification, Worldwide Networking, and Rebuilding a new clientele base

Target Audience:

Virologists
Microbiologists
Doctors
Healthcare Faculty
Associations and Societies
Buisiness Entrepreneurs
Oncologists
Professors
Industrialist
Young researchers
Researchers
Laboratories

Who Should Attend:

Virologists
Microbiologists
Doctors
Healthcare Faculty
Associations and Societies
Buisiness Entrepreneurs
Oncologists
Professors
Industrialist
Young researchers
Researchers
Laboratories

Sessions & Tracks

Track 1: General Virology

Infections and infection-like organic entities, which are sub-infinitely small parasitic microorganisms with hereditary material coated in a protein coat, are studied in the field of virology. It focuses on the creation, organization, and growth of infections as well as their tactics for contaminating and using host cells for cellular reproduction, their collaboration with human physiology and resistance, the diseases they cause, disengagement and culture procedures, and their use in diagnostic and therapeutic procedures. A branch of microbiology is known as virology.

Sub tracks:

Immunology and Molecular biology
Aspects of Virus infection in the Clinic
Infection-Host Interactions
Retroviruses
Viral RNA
Antiviral Substances

RELATED CONFERENCE

Related Association

Track 2: Emerging Infectious Diseases

Emerging infectious illnesses are those that have recently entered a population, whose incidence or geographic range is rapidly expanding, or which threatens to do so shortly. The World Health Organization warned that infectious diseases are emerging at an unprecedented rate in a report published in 2007. Since the 1970s, over 40 infectious diseases have been discovered, including COVID-19, which is brought on by the SARS-CoV-2 coronavirus, SARS, MERS, Ebola, chikungunya, swine flu, and Zika. Living in more densely populated areas, traveling over distances that are much greater than in the past, and coming into closer contact with wild animals raise severe concerns about the potential for new infectious diseases to spread swiftly and start global epidemics like influenza and many others. Such illnesses pay little attention to international boundaries. The small number of organisms that are capable of effective human-to-human transmission might generate significant national and international concern as potential epidemics or pandemic triggers. They may have a range of therapeutic, societal, and economic repercussions.

Sub tracks:

Clinical Characteristics and Results
Return of an infectious disease
Clinical Qualities and Results
Epidemiology
Zoonotic Illness

RELATED CONFERENCE

Related Association

Institute of Human Virology | Rocky Mountain Virology | Hellenic Society of Virology | Pan-American | | European Society for Medical Oncology | Indian Society of Oncology | American Society for Radiation Oncology | Association for Molecular Pathology | Berkshire Surrey Pathology Service | International Academy of Pathology | Senckenberg Institute of Pathology | Sir William Dunn School of Pathology | Intersociety Council for Pathology Information | American Society for Microbiology | Microbiology Society | Microbiology Society of India || American Society for Biochemistry and Molecular Biology | The Society for Molecular Biology & Evolution | International Union of Biochemistry and Molecular Biology | The German Society for Molecular Biology | Molecular Biology and Evolution | Turkish Society of Microbiology | European Society of Clinical Microbiology | World Microbiology society | Brazilian Microbiology Society

Track 3: SARS-CoV-2 Infection in Macrophages

Virologists have discovered a receptor known as CD169 (also known as Siglec1) that is only expressed in macrophages and is responsible for the hyper-inflammatory reaction of macrophages following SARS-CoV-2 infection. These results could explain why SARS-CoV-2 infection of macrophages in COVID-19 patients' lungs causes inflammatory reactions. It has been proposed that the severity of COVID-19 illness is influenced by the dysregulation of macrophages during SARS-CoV-2 infection and the excessive production of pro-inflammatory cytokines by these macrophages. However, it is still unknown what causes macrophages to react in a hyper-inflammatory manner. The SARS-CoV-2 receptor ACE2 is not expressed by these macrophages. Rather, a lectin called CD169 that detects the SARS-CoV-2 spike protein helped SARS-CoV-2 enter macrophages.

The virologists propose that the abnormal inflammation linked to severe COVID-19 illness may be influenced by the ongoing activation of viral sensing systems that identify these viral replication intermediates in macrophages. Future study is required, according to the virologists, to examine the molecular specifics of this distinct virus entrance mechanism, the limited virus replication in macrophages, and how this entry mechanism varies from the traditional ACE2-mediated entry pathway. Importantly, it is necessary to take into account treatments that aim to block this alternative viral entry pathway as they may help to lessen the negative consequences of SARS-CoV-2 infection in macrophages.

Sub tracks:

SARS-CoV-2
Macrophage viral infections
CD169
Entry pathway

RELATED CONFERENCE

International Virology Conference on Plant Virology and Molecular biology | International Virology Conference on Microbiology & Infectious diseases |International Virology Conference on Virology, Immunology, and Infectiology | International Virology Conference on Plant Viruses and Virology| International Virology Conference on Plant Virology | International Microbiology conference 2023 | Microbiology conferences |virology and Microbiology Conference | Microbiology conference 2023 | | Oncology Conference | Annual Oncology Conference | International Oncology Conference 2023 |

Related Association

Track 4: Virology and Parasitology in Medicine.

Medical microbiology and virology (MMV) is concerned with the diagnosis, treatment, and prevention of infection dissemination in hospitals and the community. Even though both of these specializations are lab-based, they are crucial to clinical infection treatment. Medical virologists perform their job in a range of locations, including labs, clinics, hospital wards, and the general public. They deal with challenges brought on by current and developing viruses like SARS and avian flu around the world, as well as HIV/AIDS and other blood-borne illnesses like hepatitis B and C. Medical virologists now have to deal with a new threat called "bioterrorism," which takes advantage of diseases like smallpox.

The seriousness of parasites as pathogens that affect public health, the environment, and the global economy is being recognized more and more. More than three billion people have one or more parasite infections, which cause varying degrees of sickness and mortality. The study of parasitic protozoa, helminths, and arthropods is known as parasitology, and these three groups have historically been the only ones covered. The anatomy, life cycle, and interactions of medical parasites with their hosts and environs are the focus of human parasitology. It is expected that parasitic infections will continue to be difficult to control, demanding increased scientific understanding to enhance control efforts.

Sub tracks:

Pathogenesis and Immunology of Virus infections
Morphology of viruses
Viral Genetics
Host cell connections
Ectoparasites
Endoparasites
Replications

RELATED CONFERENCE

International Virology Conference on Virology and viral |International Virology Conference on Veterinary Virology and viral oncology | Microbiology conferences | Oncology Conference | Immunology Conference | Oncology Conferences | virology and Oncology Conference | virology and Immunology Conference 2023 | virology and Microbiology Conference | Microbiology conference 2023 || Oncology Conference | Annual Oncology Conference | International Oncology Conference 2023 | Annual Immunology Conference | Oncology Conference 2023 | pathology Conference 2023 | International Virology Conference on Virology| International Virology Conference on Virology and viral pathology| International Virology Conference on Molecular Biology and Microbiology |International Virology Conference on Virology and Influenza | International Microbiology conference 2023 | Microbiology conferences |virology and Microbiology Conference | Microbiology conference 2023 |

Related Association

Track 5: Protein Structure of the Hepatitis C Virus

A long-needed structural data on HCV lays the way for logical vaccine development by virology researchers against this very challenging target by placing a multitude of prior observations into a structural perspective. Two million Americans are estimated to be among the 60 million persons worldwide who have chronic HCV infections. A "silent" infection caused by the virus usually persists for decades before liver damage is severe enough to cause symptoms. The virus affects liver cells. It is a major contributor to primary liver cancer, chronic liver disease, and liver transplants. Although the virus's origins are unknown, it is believed to have appeared at least a few hundred years ago and spread internationally, particularly through blood transfusions, in the second half of the 20th century.

Although the virus was mostly eradicated from blood banks following its original detection in 1989, it still spreads primarily through intravenous drug users exchanging needles in industrialized countries and through the use of sterile medical equipment in impoverished nations. The most popular HCV antiviral medications are efficient but considerably too pricey for widespread use. A successful vaccination may someday make HCV no longer a problem for public health. But no such vaccine has ever been created, in large part due to the extraordinarily challenging nature of understanding the HCV envelope protein complex, which is made up of the viral proteins E1 and E2.

Sub tracks:

Proteomics of HCV
Types of HCV
Virus transmission
Testing and diagnosis

RELATED CONFERENCE

Related Association

Track 6: Steps in Pursuit of HIV Cure

This study is one of the first to be conducted on humans, and it shows how to increase the body's resistance to HIV even when current conventional therapy is halted. Therefore, we see the study as a critical first step toward treatment. Even though there is currently no therapy for HIV and no vaccine to prevent it, current standard care is quite successful in halting the illness. The so-called antiretroviral medication available to HIV patients today reduces the quantity of the virus in the blood and partially recovers the immunology system. Nevertheless, whether the patient is 10 or 20 years into the course of therapy, the amount of virus in the blood rises within weeks to the same level as before the normal treatment began if the standard treatment is stopped.

According to a study, individuals with HIV who are newly diagnosed and are given monoclonal antibodies in addition to their standard HIV medication experience a quicker decline in viral load after treatment begins and develop better HIV immunity. Additionally, when these individuals stop taking their standard HIV medication, their immune systems can partially or completely suppress the virus.

According to the first successful clinical study in virology, the experiment's underlying assumption is that the monoclonal antibodies aid the immune system in identifying and eliminating the contaminated cells. Additionally, the antibodies attach to viruses that end up in the lymph nodes in bulky complexes, promoting the development of HIV immunity in certain immune cells among other things. By doing this, the body may be able to stop the virus from spreading and "guard" itself from the damage brought on by HIV infection. If the regular course of therapy is stopped, prior clinical studies with investigational drugs have not revealed any appreciable impact on the patient's immunity to HIV or the immune system's capacity to suppress the virus.

Sub tracks:

Virus in hiding
Anti-bodies
Optimized treatment
Antiretroviral medication

RELATED CONFERENCE

Related Association

Track 7: New Lassa Fever Therapy

The deadly Lassa virus is indigenous to West Africa and is mostly spread by rodents. Lassa fever is brought on by the virus; it affects up to 300,000 people a year and often begins with flu-like symptoms before progressing to more serious sickness, death, and long-lasting effects including deafness. The Lassa virus is particularly harmful to expectant mothers since approximately 90% of infections during pregnancy result in death. Glycoproteins are used by Lassa to enter host cells and start an infection. The glycoprotein structure of Hastie provided virologists with an understanding of their opponents. The scientists uncovered precisely how the three antibodies in Arevirumab-3 neutralize the Lassa virus based on the high-resolution structures and several functional experiments.

The area of the glycoprotein is where three molecules (called protomers) come together to form a "trimer," a kind of twisted trefoil, as Hastie describes it. Lassa would normally use this region of the glycoprotein to bind with receptors on host cells, but the latest structure shows how a single 8.9F jumps in and binds to all three protomers simultaneously to block infection. Meanwhile, the neutralizing antibody called 12.1F binds to just one protomer in the three-sided trimer. 12.1F would be abundant in any therapeutic. Each 12.1F antibody can attach to a protomer and move as a trio to help neutralize the virus. The Lassa virus is the target of copies of antibody 37.2D that attach in a way that binds neighboring protomers together. Since the Lassa virus needs to open up its trimer to infect host cells, this antibody activity is a major challenge for the virus. Its entrance mechanism is locked up and impossible to operate with 37.2D on the scene.

Sub tracks:

Transmission and Remedy
Therapeutical methods
Antibodies
Glycoproteins and Lassa

RELATED CONFERENCE

Related Association

Spanish Society for Virology | European Society for Clinical Virology | Italian Society for Virology | Brazilian Society for Virology | National Institute of Virology| Spanish Society for Virology | Brazilian Society for Virology | American Society of Clinical Oncology | European Society for Medical Oncology | Indian Society of Oncology | American Society for Radiation Oncology | American Society of Clinical Oncology | British Neuro-Oncology Society | Chinese Society for Clinical Oncology | Intersociety Council for Pathology Information | American Society for Investigative Pathology |American Society for Microbiology | Microbiology Society | Microbiology Society of India | Turkish Society of Microbiology | German Society for Microbiology | European Society of Clinical Microbiology | World Microbiology society || American Society for Biochemistry and Molecular Biology | The Society for Molecular Biology & Evolution | International Union of Biochemistry and Molecular Biology | The German Society for Molecular Biology | Molecular Biology and Evolution | Brazilian Microbiology Society

Track 8: Viral Infection In Down Syndrome

Viral infections are less common in people with Down syndrome, but when they do occur, the sickness they cause is more severe. Increasing levels of an antiviral cytokine type I interferon (IFN-I), which is largely coded for by chromosome 21, are the source of this, according to recent research. Increased IFN-I levels trigger an initial overreaction of the immune system, but the body overcompensates to lower inflammation, leaving the body more vulnerable to viral infection later. While immunological dysfunction is evident in patients with Down syndrome, the exact mechanism by which a supernumerary chromosome 21 results in the dysregulation of defenses is yet unknown.

The virologists studied fibroblasts and white blood cells produced by people with and without Down syndrome at both the mRNA and protein levels to fill this information gap. They concentrated on the chromosome 21-based IFN-I receptor subunits IFNAR1 and IFNAR2, which are powerful antiviral cytokines. Independent of trisomy 21, the virologists discovered that elevated IFNAR2 expression was sufficient to cause the IFN-I hypersensitivity seen in Down syndrome. But afterward, the excessively powerful IFN-I signaling cascade activated a protein called USP18, a strong IFNAR negative regulator, to provide excessive negative feedback. Further IFN-I responses and antiviral responses were subsequently inhibited by this approach. Together, the data show that Down syndrome is predisposed to oscillations of hyper- and hypo-responses to IFN-I, which reduce the incidence of illness and raise infection-related morbidity and death.

Sub tracks:

IFN-I
USP18
Immune Dysregulation
RS virus and Down syndrome

RELATED CONFERENCE

International Virology Conference on Virology and viral pathology| International Virology Conference on Molecular Biology and Microbe Oncology| International Virology Conference on Virology and Animal Pathology | International Microbiology conference 2023 | Pathology Conference | Microbiology conferences | Oncology Conference | Immunology Conference | Oncology Conferences | virology and Oncology Conference | International Virology Conference on Virology and Pathology| International Virology Conference on Molecular Biology and Microbiology | International Virology Conference on Molecular Biology and Zoonotic Oncology| International Virology Conference on Virology and viral Pathology | International Microbiology conference 2023 | Microbiology conferences |virology and Microbiology Conference | Microbiology conference 2023 | | Oncology Conference | Annual Oncology Conference | International Oncology Conference 2023 |

Related Association

Track 9: Virus Universe using Metatranscriptome Mining

The development of metatranscriptomics aids in the discovery of key characteristics of the Earth's RNA virome. Virologists found many new viruses in this study that shed light on the variety, host range, and evolution of RNA viruses. The discovery of 2.5 million RNA virus-derived sequences came through the mining of more than 5,150 different metatranscriptomes from existing sources. The variety of known RNA viruses has increased five times as a result of this development. The most unique populations are divided into two groupings that might constitute new phyla, while others are categorized into multiple new classes and orders. The most significant finding is the sharp rise in the variety and quantity of bacteria-infecting viruses, which are now known to make up a far larger proportion of RNA viruses than previously believed. A significant resource for RNA virology should be the enormous collection of novel RNA virus genomes, which offers insight into the evolution of RNA viruses.

Sub tracks:

Metatranscriptomics
RNA virome
metagenomics and metatranscriptomics
SAMSA2

RELATED CONFERENCE

Related Association

Spanish Society for Virology | Canadian Society for Virology |Australasian Virology Society |Society for Virology |European Society for Medical Oncology | Indian Society of Oncology || American Society for Biochemistry and Molecular Biology | The Society for Molecular Biology & Evolution | International Union of Biochemistry and Molecular Biology | The German Society for Molecular Biology | Molecular Biology and Evolution | American Society for Radiation Oncology | American Society of Clinical Oncology | British Neuro-Oncology Society | Chinese Society for Clinical Oncology | Intersociety Council for Pathology Information | American Society for Investigative Pathology | American Society for Microbiology | Microbiology Society | Microbiology Society of India | Turkish Society of Microbiology | German Society for Microbiology | European Society of Clinical Microbiology | World Microbiology society | Brazilian Microbiology Society

Track 10: Neurological Risk Of HIV

Despite having well-controlled HIV illness, a new study in the field of virology from Zambia shows that children with HIV are considerably more likely to do poorly on neurological tests, raising the possibility that they may have cognitive and mental health problems. However, early intervention is also suggested by the studies. Children who are exposed to the virus before birthing are known to have an increased risk of developing neurocognitive and mental issues, such as depression, when they get older. HIV continues to be a significant worldwide health burden. HIV has a disproportionately large impact on Sub-Saharan Africa, accounting for over 70% of all infections worldwide. Even though combination antiretroviral treatment (cART) is widely available, many infected children continue to experience the neurocognitive and mental abnormalities that are linked to HIV, including depression and delayed academic development. Findings imply that one of the most crucial things we can do is identify children with HIV early and start them on antiretroviral medication since children perform considerably better intellectually if they don't get ill from HIV. The dietary component is another important element in this.

Sub tracks:

Neurology and virology.
vacuolar myelopathy.
Lymphomas.
Neurosyphilis.
Diagnosis & Treatment.

RELATED CONFERENCE

Related Association

Spanish Society for Virology | Canadian Society for Virology |Australasian Virology Society |Society for Virology. | Intersociety Council for Pathology Information | American Society for Investigative Pathology | Brazilian Society for Virology | American Society of Clinical Oncology | European Society for Medical Oncology | American Society for Microbiology | Microbiology Society | Microbiology Society of India | Turkish Society of Microbiology || American Society for Biochemistry and Molecular Biology | The Society for Molecular Biology & Evolution | International Union of Biochemistry and Molecular Biology | The German Society for Molecular Biology | Molecular Biology and Evolution | German Society for Hygiene and Microbiology | European Society of Clinical Microbiology | World Microbiology society | Brazilian Microbiology Society

Track 11: Poliovirus Attack.

The terrible enterovirus family, which includes numerous common colds, includes the poliovirus. Since technology has not yet enabled us to see thus deeply within the cells, it has been known for some time that enteroviruses significantly reorganize the inside of infected hosts. Virologists have now been able to capture three-dimensional pictures of how the poliovirus develops and colonizes human cells for the first time thanks to a recent study. By observing areas with half-assembled viruses, the virologists were able to pinpoint the location in the cell where the poliovirus creates new virus particles. This " factory" in the cell, which resembled autophagy, a normally occurring cellular process, turned out to be present. The 2016 Nobel Prize in Physiology or Medicine was awarded for the discovery of the cell mechanism called autophagy.

Autophagy often works to destroy substances that the cell wishes to get rid of, such as virus particles. However, the poliovirus can rewire this anti-virus defensive system such that it instead creates additional viruses. The scientists discovered that some proteins are particularly significant. The virus uses the VSP34 protein to create new particles. When the virologists blocked VSP34, they could observe that the virus could mainly only form half particles and could seldom assemble whole viruses. ULK1, another significant protein, inhibits the development of viruses. The number of viruses multiplied, as the virologists could observe when this protein was suppressed. Given that the illness was seen as nearly eliminated, a fall in vaccination rates as well as rising vaccine resistance may be contributing factors in wealthy nations where polio has returned.

Sub tracks:

Poliomyelitis
Post-polio syndrome
Types
Brain Physiology

RELATED CONFERENCE

International Virology Conference on Plant Pathology and Plant Virology| International Virology Conference on Plant Virology and Animal Oncology | virology and Immunology Conference 2023 | virology and Microbiology Conference | Microbiology conference 2023 | Annual Immunology Conference | Oncology Conference 2023 | pathology Conference 2023 | Immunology Conference 2023 | Annual Oncology Conference |Virology and Oncology Conference | International Virology Conference on Veterinary pathology and Virology | International Virology Conference on Biotechnology and Veterinary Virology| International Virology Conference on Molecular Biology and oncology | International Microbiology conference 2023 | Microbiology conferences |virology and Microbiology Conference | Microbiology conference 2023 |

Related Association

Track 12: Therapeutic viruses and Cancer cells

Despite the immune system's extensive defensive network's outstanding strength, one kind of threat is particularly difficult to eliminate. This develops when the body's cells go renegade, which causes the cancer phenomena. A recent study describes how employing the myxoma virus in combination with immunotherapy and virotherapy offers patients with cancer that are resistant to treatment fresh hope. The strategy combines two strategies that have each had significant success in treating certain malignancies. The study in virology explains how oncolytic virotherapy, a method that employs viruses to combat cancer, can work in conjunction with currently used immunotherapy methods to enhance the immune system's ability to effectively target and eradicate cancer cells. The immune system is made up of a variety of specialized cells that are created to patrol the body and react to dangers.

The immune system is engaged in an ongoing arms race with infections as they develop complex strategies to evade immune protection, spread throughout the body, and lead to disease. The new study emphasizes how immunotherapy can overcome the cancer resistance barrier when it is combined with virotherapy, specifically using T cells that have been infected with myxoma. Myxoma can directly target and destroy cancer cells, but it is more beneficial when it causes autolysis, a peculiar type of T-cell-directed cell death.

Apoptosis and pyroptosis, two other types of programmed cancer cell death generated by T-cells, are strengthened by this type of cell death. Cancerous cells nearby the ones the therapy is targeting are also eliminated during myxoma-mediated autosis, a process known as bystander death. Even in solid tumors that are notoriously difficult to cure, this action can significantly increase the aggressive eradication of cancer cells by dual therapy. To allow CAR T-cells or TCR cells to infiltrate the tumor environment, grow, and activate, a combined myxoma-immunotherapy method has the potential to convert so-called "cold tumors," which avoid immune system identification, into "hot tumors," which immune cells can recognize and eradicate.

Sub tracks:

viral immunotherapy
Oncolytic Viruses
Friendly Viruses
Cancer cells
Myxoma.

RELATED CONFERENCE

International Virology Conference on Virology and viral pathology| International Virology Conference on Molecular Biology and Microbe Oncology| International Virology Conference on Virology and Animal Pathology | International Microbiology conference 2023 | Pathology Conference | Microbiology conferences Oncology Conference | Immunology Conference | Oncology Conferences | virology and Oncology Conference | virology and Immunology Conference 2023 | virology and Microbiology Conference | Microbiology conference 2023 | International Virology Conference on Virology and Pathology| International Virology Conference on Molecular Biology and Microbiology | International Microbiology conference 2023 | Microbiology conferences |virology and Microbiology Conference | Microbiology conference 2023 |

Related Association

Track 13: Broad-Spectrum Antiviral Therapies.

The body's first line of defense against any foreign invader is triggered when a particular enzyme, present in all cells, is blocked, according to studies conducted on mice and cell cultures. This reaction significantly reduced particle proliferation when tested by several virus types in the study and shielded mouse lungs from injury. This discovery was made possible in part by a method the virologists developed to pinpoint the site of an RNA alteration they were researching and to identify the enzyme responsible for the change. They were able to deduce from the mapping that this enzyme functions in mammal hosts, not viruses, who wish to infect them. Human respiratory syncytial virus and human metapneumovirus, two viruses that can cause serious respiratory infections in young children and the elderly, as well as the Sendai virus from mice, the vesicular stomatitis virus found in cattle, and the DNA virus herpes simplex were all tested against the immune response in this study. The virologists reported early findings from prior investigations in cell cultures revealed the SARS-CoV-2 virus may be similarly controlled by this antiviral approach. Replication and gene expression of all of these viruses were dramatically decreased when the enzyme was stopped. To start the immune system's reaction, the RNA alteration known as cytosine-5 methylation, or m5C, has to be changed. It is one of around 170 documented chemical alterations to RNA molecules seen in living things that have an array of effects on biological processes.

Sub tracks:

Broad-spectrum antivirals
Cytosine-5 methylation
Respiratory syncytial virus
Human metapneumovirus

RELATED CONFERENCE

Related Association

Track 14: Vaccines Production and Clinical trials

This research in virology is a phase III clinical trial that is randomized, double-blinded, multi-center, and placebo-controlled for individuals ages 18 to 59. This investigation's goal is to assess the SARS-CoV-2 inactivated vaccine's effectiveness, safety, and immunogenicity. Sinovac Research & Development Co., Ltd. produced both the experimental vaccination and a placebo. 13.000 subjects in total will be registered. On the scheduled day of day 0,14, the subject will either be given two doses of the experimental vaccination or a placebo. The trial will involve two distinct cohorts, as anticipated.

Healthcare professionals in the high-risk category (K-1) will make up the first cohort, while those at normal risk will make up the second cohort (K-2). After 1300 participants have had their second round of vaccination, the safety data will be reviewed by the data safety monitoring board without compromising the blinding process. If there are no safety concerns, the K2 cohort will continue to receive vaccinations. The K-1 cohort will have 1.300 participants, 650 of whom will participate in the SARS-CoV-2 vaccination and placebo arms. It was intended to include 7.650 participants in the SARS-CoV-2 vaccination group and 3.500 volunteers in the placebo group in the K-2 cohort (the typical risk category for COVID-19).

Sub tracks:

Discovery
Phases
Immunogenicity
Stages

RELATED CONFERENCE

Related Association

Track 15: Monoclonal Antibodies

The EBV virus goes latent in the body after infection, although it can occasionally be reawakened. It is the main cause of infectious mononucleosis and is linked to multiple sclerosis, Hodgkin lymphoma, and several malignancies, including Hodgkin lymphoma. Severe symptoms and problems from EBV infection are more common in immunocompromised individuals than in immunocompetent individuals, such as transplant patients. The scientists create several experimental mAbs that target two important proteins called gH and gL that are present on the surface of EBV. The two proteins are known to facilitate EBV infection and fusion with human cells. When the investigational mAbs were tested in a lab setting, human B cells and epithelial cells, which line the throat at the initial site of EBV infection, were not infected by EBV. Virologists found several vulnerable locations to target by analyzing the structure of the mAbs and their two surface proteins using X-ray crystallography and advanced microscopy. One of the experimental monoclonal antibodies, known as mAb 769B10, offered nearly full protection against EBV infection in mice. Additionally, the mAb prevented EBV lymphoma in all examined animals. The results demonstrate promising EBV vaccine targets and the potential of investigational mAbs to prevent or treat EBV infection in immunocompromised patients most vulnerable to severe EBV-related illness.

Sub tracks:

Myeloma cells
EBV
IgG
Monoclonal

RELATED CONFERENCE

Related Association

Track 16: Influenza Immune Defense

In the globe, IAVs cause between 250,000 and 500,000 fatalities annually. An immune response made up of several molecular mechanisms starts when IAV infects its host. IAV may infect a variety of species, and although certain host responses are common, physiological and genetic variations among these species can influence these responses. The study identified several important defensive mechanisms particular to tissues and species by using RNA sequencing to assess gene expression over time in cells and tissues taken from IAV-infected humans, ferrets, and mice. It has been demonstrated that the Tudor domain-containing protein, a kind of protein implicated in epigenetic regulation, encoded by the gene TDRD7 plays a crucial role in the immunological defense mechanisms against IAV in all species. After making this finding, the virologists carried out additional studies in which they inhibited the activity of TDRD7, which led to an increase in viral replication in IAV-infected mice. To create flu treatments that work, it is crucial to understand both common and species-specific reactions to influenza. This information may also be used to guide future studies on other respiratory illnesses like COVID-19.

Sub tracks:

TDRD7
Tudor domain-containing protein
Antigenic drift
Pathophysiology
Antiviral chemoprophylaxis
Prognosis
Epidemiology
Etymology

RELATED CONFERENCE

Related Association

Canadian Society for Virology | Brazilian Society for Virology | National Institute of Virology| Spanish Society for Virology | Brazilian Society for Virology | American Society for Clinical Pathology.| The European Society of Pathology | Association for Molecular Pathology | American Society of Cytopathology | Association for Molecular Pathology | Berkshire Surrey Pathology Service | International Academy of Pathology | Senckenberg Institute of Pathology | Indian Society of Oncology | American Society for Radiation Oncology | American Society of Clinical Oncology | British Neuro-Oncology Society | Chinese Society for Clinical Oncology | American Society for Microbiology | Microbiology Society | Microbiology Society of India || American Society for Biochemistry and Molecular Biology | The Society for Molecular Biology & Evolution | International Union of Biochemistry and Molecular Biology | The German Society for Molecular Biology | Molecular Biology and Evolution | Turkish Society of Microbiology | European Society of Clinical Microbiology | World Microbiology society | Brazilian Microbiology Society

Track 17: Avian Virology

The current North American epidemic has affected over 40 species of birds, including raptors like owls and hawks as well as songbirds like crows and sparrows. Compared to the North American epidemic in 2014, this one is affecting a wider variety of species and has a larger geographic reach. Despite being zoonotic, there is extremely little risk to humans from avian influenza. People who often handle birds, such as wildlife professionals, poultry workers, or home chicken owners, are at a slightly higher risk. The first human case of avian influenza in North America during this outbreak was recently identified in a guy in Colorado. He was involved in the culling of chickens and contracted an infection from a sick fowl. He experienced little symptoms, was kept isolated, and made a full recovery, according to the Centers for Disease Control and Prevention. His minor symptoms are a matter of concern since, as Hill points out, it makes the virus more difficult to detect and monitor because infected people may disregard their weak symptoms and forego medical attention, much with COVID-19.

The 2014 bird flu pandemic eventually subsided, but the 2022 outbreak is very different from the previous outbreak, according to him, therefore that won't likely happen this time. In contrast to this epidemic, the viruses discovered in North America in 2014 only comprised fragments of the highly dangerous H5 viruses. Also, it appears that this assault has expanded more quickly than the previous one. In addition, according to Hill's study, avian flu epidemics tend to grow in size and frequency over time.

Sub tracks:

Paramyxoviruses
Metapneumoviruses
Reovirus
Leukosis Virus
Avian viruses

RELATED CONFERENCE

Related Association

Track 18: Future of Virology

For thousands of years, viruses and viral infections have been the focus of research, agriculture, and medicine. Some of our greatest struggles and achievements have involved virology. Many methods used to examine cellular genes, such as restriction enzyme mapping, molecular cloning, and genome sequencing, were initially created and refined by utilizing smaller and more manipulable viral genomes. Indeed, virology laboratories served as the breeding ground for the fields of genetic engineering and biotechnology.

Viruses and viral gene products have also become important tools for understanding many biological processes and, possibly, for the treatment of illness. These techniques include reverse transcriptase, which is used to create cDNA, viral vectors, which transmit genes and produce proteins, transgenic animals, vaccines, and oncolytic treatment, which aims to leverage some viruses' ability to selectively target and destroy cancer cells. Studies are being conducted to see if this method is effective in treating human tumors. In a recent study, all mice given the protein-based immunization survived when exposed to lethal doses of the COVID-19-causing SARS-CoV-2 virus.

The SARS-CoV-2 exposure did not result in any lung damage in any of the mice. During a 14-day trial, every mouse who did not receive the nanoparticle vaccine perished. The nanoparticles that contain the immunological target are known as SNAs, and they are a kind of globular DNA that can infiltrate immune cells and excite them very well. Over 60 different cell types have been used to evaluate SNAs. The ideal ratio between the density of the SNA's shell and core that yields the strongest response was established experimentally. SNA vaccines have been used to treat triple-negative breast cancer in mice, and more cancer-related vaccines are currently being developed. It was mostly practical to use COVID-19 as a case study to contrast how well the vaccine performed. However, it also draws attention to the SNA's larger significance as a platform for infectious diseases.

Although the case study's results are quite impressive, the intention was not to outperform the COVID vaccines currently on the market. Since there will eventually be another emergent disease, we are preparing for the next mutation or the next illness that requires a highly structured vaccine.

Sub tracks:

Innovation
Future pathway
Scopes.
Upcoming Techniques
Mutating virus

RELATED CONFERENCE

Related Association

Track 19: Acute Viral Diseases

Emerging irresistible infections are defined as infections that have recently appeared in a population, are becoming more frequent or widespread geographically, or are taking measures to do so. The World Health Organization cautioned in a report from 2007 that infectious diseases are spreading at an unusually rapid rate. Since the 1970s, over 40 infectious diseases have been discovered, including COVID-19, which is caused by the SARS-CoV-2 Covid, SARS, MERS, Ebola, Chikungunya, and avian, pig, and Zika influenza. Traveling more frequently and over longer distances than before, living in more densely populated areas, and coming into closer contact with wild animals all increase the risk of new infectious diseases spreading quickly and causing widespread pandemics, which is a serious issue. Such diseases don't pay much attention to waiting in queues. As potential plague or pandemic causes, the small number of organisms capable of effective human-to-human transmission might raise substantial public and global concerns. They may provide a range of financial, cultural, and healing effects.

Sub tracks:

Monitoring and Seroprevalence
Infectious disease recurrence
Disease transmission and global health
Clinical Characteristics and Results

RELATED CONFERENCE

International Virology Conference on Molecular Biology and Microbiology |International Virology Conference on Molecular Biology and Microbial pathology |International Virology Conference on Virology and viral Oncology | virology, and Immunology Conference 2023 | virology and Microbiology Conference | Microbiology conference 2023 | Annual Immunology Conference | Oncology Conference 2023 | pathology Conference 2023 | Immunology Conference 2023 | Annual Oncology Conference |Virology and Oncology Conference | International Virology Conference on Molecular Biology and Microbial oncology| International Virology Conference on Molecular Biology and Microbiology | International Virology Conference on Plant Virology and viral pathology | International Microbiology conference 2023 | Microbiology conferences |virology and Microbiology Conference | Microbiology conference 2023 |

Related Association

Market Analysis

The market analysis of virology shows that there will be a CAGR of 8.20% during the forecast period 2022 to 2029. According to Data Bridge Market Research, the Virology Testing Market, which had a value of USD 4,108.27 million in 2021, will soar to USD 7717.51 million by 2029 and have a CAGR of 8.20% from 2022 to 2029.

The global virology testing market describes the past, present, and future of the sector's marketing strategies and goods. They also go into depth on sales and distribution networks, present and future market trends, and technical and economic advancements. The Virology Testing Market Survey Document provides information on the most recent industry shares, growths, and strategies used by key market competitors. This market report also confirms the top players globally in the virology testing market to provide a better knowledge of the industry. Their important marketing strategies and advertising businesses have been highlighted.

The primary driving forces behind the market are the mode of infection and utilization of host cells for reproduction, their interaction with the physiology and immunity of the host organism, the illnesses they cause, the methods to isolate and grow them, and their usage in research and therapy. As obligatory intracellular molecular parasites, viruses cannot divide in two via binary fission. Typically, only one kind of nucleic acid—DNA or RNA—contains the information required for viral reproduction in viruses.

Public education campaigns on topics like the flu, the Zika virus, STDs, AIDS, and the Ebola virus are important for raising awareness among the general public and ultimately affecting the market growth. The healthcare industry's demands for prevention and treatment are continuously met by the virology market. However, several illnesses continue to necessitate R&D of innovative applications, fuelling additional market expansion. Applications for virology are used in a variety of therapies and diagnostic procedures, which is boosting market expansion.

viral tests assist in identifying viruses that cause infections. Viruses may be identified using a variety of techniques, including hemagglutination tests, specific antibody detection, antigen detection, viral nucleic acid detection, and gene sequencing. Interferon, antiviral treatment, and immunoprophylaxis are all effective ways to manage viral infection. The market is segmented into Diagnostic tests: DNA Viruses, RNA Viruses, Prions Diagnostic Tests, and Other viral Tests based on product type.

Industry view:

Diagnostic methods that help in the early diagnosis of illnesses including hepatitis, influenza, HIV, sexually transmitted diseases, RCV, and other viruses-related disorders are included in viral testing. In the supplied sample, virology testing checks for the presence of viral antigens, nucleic acids, and antibodies. More than 100 viral diseases have been discovered.

The market for virology testing is anticipated to expand significantly. The new, highly accurate molecular-based virology testing techniques, such as immunoassay, mass spectrometry-based detection techniques, nucleic acid-based amplification testing techniques, and next-generation genome sequencing techniques, can quickly and accurately diagnose a variety of viral infections.

The two end-use categories that now account for about half of the worldwide market share, hospitals, and laboratories, are expected to remain the most dominant. In terms of geography, the virology market is divided into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, the Middle East, and Africa. Due to technical improvements like portable diagnostics, North America is the largest market, with the U.S. dominating it. Over the projection period, North America is anticipated to keep its strong market position.

Generally, there are several options for virologists. Even more than before, there is a growing demand for specialists in the health world. The opportunity to engage in virology and acquire new skills and information to further their careers is available to virologists.

Regional Analysis:

The United States, Canada, and Mexico make up North America, while Germany, France, the United Kingdom, the Netherlands, Switzerland, Belgium, Russia, Italy, Spain, and Turkey make up Europe. Other nations covered in the report include China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and the rest of Asia-Pacific (APAC), as well as South Africa, the United Arab Emirates, Saudi Arabia, Israel, Egypt Israel, and the rest of the Middle East and Africa (MEA).

Due to advancements in portable diagnostic technology, North America currently controls the majority of the market for virology testing.

Due to its sophisticated infrastructure development, Asia-Pacific is anticipated to expand at the greatest pace throughout the projected period of 2022 to 2029.

Germany spends more funds on virology research.

The North American virology market is anticipated to increase from US$ 1,531.21 million in 2021 to US$ 1,984.33 million in 2028, growing at a CAGR of 3.8% over that time.

The market for virology tests is categorized by diagnostic method, specific product, end consumer, and territory.

Specific product

Equipment
Assay kits
Supplies

Territory

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

End Consumer

Hospitals
Diagnostic Centre
Blood Banks
Others

Diagnostic Methods

Method of Molecular Diagnostics
- PCR-based methods
- NGS-based methods

Method based on an immunoassay
Based on Mass Spectroscopy

COMPANIES RELATED TO VIROLOGY

· Abalos Therapeutics

·AbbVie

·Abintus

·Abivax

·Apath

·Exact Diagnostics

·GenTarget

·GeoVax

·Immune Technology Corp

·Novavax

·Oxford Genetics

·Texcell

·Viracta Therapeutics

·Virapur

·ViraTherapeutics (Boehringer Ingelheim)

·ViroStat

TOP UNIVERSITIES IN VIROLOGY RESEARCH

·University of Oxford

·Harvard University

·Johns Hopkins University

·University of Hong Kong

·Imperial College London

·University of Washington Seattle

·University College London

·University of California San Francisco

·Universite de Paris

·University of Melbourne

·London School of Hygiene & Tropical Medicine

Past Conference Report

PULSUS Conferences successfully hosted the "6th World Virtual Congress on Virology, Influenza and Infectious Diseases" on December 17–18, 2021, with a lot of help from our Collaborators and the Organizing Committee. We would like to express our gratitude to the members of the organizing committee who helped make this event a huge success as well as the moderator who helped make the event a huge success.

It wouldn't have been possible without the cooperation of our Media Partners who assisted us in marketing this event, thus we would like to express our gratitude to them.

We also want to express our gratitude to all of the speakers, poster presenters, and delegates who gave presentations and shared their findings with our peer network.

Our Highlighted speakers were:

Lanying Du | USA

Hina Ashraf | Government Sadiq College Women’s University, Pakistan

Julien van Grevenynghe | Centre INRS Institute Armand Frappier, Canada

Wasfi Fares | Institut Pasteur de Tunis | PASTEURTN Â· Laboratory of Vector Ecology Taiwan

Ola Elmadani | Mansoura University, Egypt

Yusuf Hussaini | Federal Polytechnic Nasarawa, Nigeria

Ali Ilter Akdag | Jamia Hamdard University, India

Trang Van | The University of Sydney, Australia

In the future, we expect to see even more support from all of these Attendees and organizations, with whom we have a wonderful relationship.

The 8th International Conference on Virology, Influenza, and Infectious Diseases will be held in Madrid, Spain on May 29–31, 2023. Pulsus Conferences is pleased to announce this conference as part of its Series of Virology.

8^th International Conference on
Virology, Influenza and Infectious Diseases

Quick Links

Theme: Discovering and Combating the Latest Research innovations In Virology

Conference Information

Welcome Message

About Conference

Sessions & Tracks

Market Analysis

· Abalos Therapeutics

·AbbVie

·Abintus

·Abivax

·Apath

·Exact Diagnostics

·GenTarget

·GeoVax

·Immune Technology Corp

·Novavax

·Oxford Genetics

·Texcell

·Viracta Therapeutics

·Virapur

·ViraTherapeutics (Boehringer Ingelheim)

·ViroStat

TOP UNIVERSITIES IN VIROLOGY RESEARCH

·University of Oxford

·Harvard University

·Johns Hopkins University

·University of Hong Kong

·Imperial College London

·University of Washington Seattle

·University College London

·University of California San Francisco

·Universite de Paris

·University of Melbourne

·London School of Hygiene & Tropical Medicine

Past Conference Report